Try our Advanced Search for more refined results
Life Sciences
-
October 24, 2025
Tricida Investors Win OK Of $14.2M Deal Over Kidney Drug
A California federal judge on Thursday granted final approval to a $14.2 million settlement that ends a class action against Tricida Inc. founder Gerrit Klaerner claiming he and the company misled investors on the approval chances for their new kidney disease drug, including nearly $4 million for plaintiffs' counsel.
-
October 24, 2025
Generic-Drug Makers Want Conn. Price Cap Blocked During Suit
A trade group for generic and biosimilar drugmakers is asking a Connecticut federal judge to block the state's new drug price cap during the pendency of its challenge, saying it illegally controls prices on sales made outside the state.
-
October 24, 2025
Eli Lilly Buying Eye Disease Biotech For Up To $262M
Ropes & Gray LLP-advised Eli Lilly said Friday it has agreed to acquire Cooley LLP-guided Adverum Biotechnologies, a clinical-stage company developing gene therapies for eye diseases, for up to roughly $262 million.
-
October 24, 2025
Abbott Wins Third Bellwether In Cow Milk Baby Formula MDL
An Illinois federal judge has given Abbott Laboratories Inc. its third bellwether win in multidistrict litigation alleging that its cow-milk-based baby formula gives infants necrotizing enterocolitis, saying the company successfully demonstrated that the plaintiff's proffered human-milk-based alternative would not be feasible.
-
October 24, 2025
Taxation With Representation: Latham, Wachtell, Gibson Dunn
In this week's Taxation With Representation, Meta announces a joint venture with Blue Owl Capital to fund the development of a data center campus in Louisiana, private equity giants acquire medical technology company Hologic Inc., and National Fuel Gas Co. buys CenterPoint Energy Inc.'s Ohio natural gas utility business.
-
October 23, 2025
NY AG Sues Vape Shop Owners For Selling To Kids
New York's attorney general is looking to permanently shut down two smoke shops and ban their owners from ever working in the vape industry again, claiming they flagrantly sold illegal flavored vapes to customers including children, according to a petition filed Oct. 23.
-
October 23, 2025
Ky. Rep. Revives Attempt To Abolish PTAB, Expand Eligibility
U.S. Rep. Thomas Massie, R-Ky., said Thursday he's again attempting to overhaul the patent system, including abolishing the Patent Trial and Appeal Board, normalizing injunctions and broadening what can be patented.
-
October 23, 2025
Chancery Maps Out Math For Hefty Drug Co. Breach Interest
A Delaware vice chancellor late Thursday issued a road map for calculating tens of millions of dollars in interest due after a ruling in June that Alexion Pharmaceuticals failed a "best efforts" duty to fulfill an autoimmune drug candidate deal with Syntimmune Inc.
-
October 23, 2025
Investor Says Biotech Co. Rigged Votes To Expand Share Pool
A stockholder of Pennsylvania-based Ocugen Inc. sued the biotech company Thursday in Delaware Chancery Court, alleging that the company's board contrived a "clever" but unlawful scheme to push through a 2024 charter amendment that expanded its authorized share count without the required majority approval.
-
October 23, 2025
RingConn Settles With Oura After ITC Import Ban
Ouraring Inc. has inked a deal allowing RingConn to keep its smart rings on the U.S. market following the U.S. International Trade Commission's decision to block Ultrahuman and RingConn from importing products it held infringed a wearable computing device patent.
-
October 23, 2025
Freshly Launched Legal Org. Plans To Protect Abortion Docs
A new legal group launched this week aims to support telehealth doctors providing abortion pills and reproductive care, and to further strengthen shield laws protecting those providers from out-of-state prosecutions.
-
October 23, 2025
Bayer Wants Full Fed. Circ. Scrutiny Of Axed Xarelto Claims
Bayer Pharma Aktiengesellschaft is urging the full Federal Circuit to scrutinize a decision that declined to revive claims in a patent covering its blockbuster blood thinner, saying Wednesday that a panel wrongly concluded the term "clinically proven effective" couldn't count toward the claims' patentability.
-
October 23, 2025
SEC Being Misled In CBD Fraud Fight, CEO Claims
The U.S. Securities and Exchange Commission has "unwittingly" taken the side of a former partner with a terminated licensing agreement, a pharmaceutical CEO told a California federal court this week, asking for summary judgment on the SEC's core claims that he defrauded investors.
-
October 23, 2025
Ex-Exec Accused Of Stealing IVF Co.'s Trade Secrets
The co-founder of a Garden State genetic testing company abruptly quit, deleted all the data on his company laptop — including the only copy of some materials — then took the trade secrets to help a competitor, according to a lawsuit filed in New Jersey federal court.
-
October 23, 2025
Eli Lilly Says Pharmacy Mass-Producing Weight Loss Drug
Drugmaker Eli Lilly is suing a compounding pharmacy in Texas federal court, alleging the pharmacy ripped off its lucrative weight loss drug, began mass-producing it, and made as much as $2 million per month last year from its misdeeds.
-
October 23, 2025
Avadel, Jazz Settle Sleep Disorder Drug Claims
Avadel Pharmaceuticals has announced it reached a global settlement with Irish rival Jazz Pharmaceuticals to dismiss their lawsuits against each other that alleged patent and antitrust violations related to sleep disorder drug Lumryz.
-
October 23, 2025
Del. Startup Accuses Ex-CEO In Chancery Of Stock Scheme
A Delaware pharmaceutical startup has sued its former CEO in the Delaware Chancery Court, accusing him of secretly enriching himself through unauthorized stock issuances and deceptive loans.
-
October 23, 2025
Feds, Ex-Magellan CEO Still Split Over Sentencing Factors
Lawyers for a former Magellan Diagnostics CEO and the government are still at odds over whether a judge should consider the product mislabeling charge she pled guilty to in March to be tantamount to fraud — an assertion the defense says is an attempt by prosecutors to "shoehorn" in allegations never put to proof.
-
October 23, 2025
Buyers Sue Colgate Over Lead Found In Kids' Toothpaste
A proposed class of buyers is suing Colgate-Palmolive Co. in California federal court, alleging that it sold children's toothpaste that contains substantial amounts of lead without warning consumers.
-
October 23, 2025
5th Circ. Revives Religious Bias Suit Over DOD Vaccine Policy
The Fifth Circuit breathed new life into a proposed class action claiming the U.S. Department of Defense unlawfully slow-walked civilian employees' requests for religious exemptions from its COVID-19 vaccination directive, saying the mandate getting rescinded didn't nullify the lawsuit.
-
October 22, 2025
Novo Nordisk Paid Patient Benefits, Not Bribes, Jury Hears
Novo Nordisk Inc. paid benefits to patients with a rare form of hemophilia and not bribes as a group of plaintiffs in an alleged kickback scheme have claimed, a Washington jury was told Wednesday during emotional testimony on the third day of a multiweek trial.
-
October 22, 2025
Judge Voids HHS Rule Banning Gender Identity Discrimination
A Mississippi federal judge on Wednesday struck down a Biden-era U.S. Department of Health and Human Services rule that protected gender-affirming care under the Affordable Care Act, ruling that federal officials exceeded their authority by broadening the definition of sex discrimination to cover gender identity.
-
October 22, 2025
Bristol-Myers $450M Payment Dispute Heads To Arbitration
A judge sitting for Delaware's Court of Chancery has sent to arbitration allegations from shareholders of a small biotechnology company acquired by Bristol-Myers Squibb that the pharmaceutical giant used trickery to avoid paying up to $450 million in milestone payments.
-
October 22, 2025
Judge Tosses Ingenus Suit Over Leukemia Treatment Patent
A Delaware federal judge has agreed to throw out a lawsuit accusing Hetero Labs Ltd. of infringing a patent covering a treatment for lymphoma and leukemia, pointing out that an Illinois federal court in a separate case already found the patent to be invalid.
-
October 22, 2025
Purdue Fights Baltimore Objection Ahead Of Ch. 11 Plan Trial
Purdue Pharma LP told a New York bankruptcy judge on Wednesday it is concerned a recent objection to its Chapter 11 plan brought by the city of Baltimore could disrupt its case just weeks before the drugmaker is set to begin trial on a deal that creditors overwhelmingly support.
Expert Analysis
-
9th Circ.'s Kickback Ruling Strengthens A Prosecutorial Tool
The Ninth Circuit's decision last month in U.S. v. Schena, interpreting the Eliminating Kickbacks in Recovery Act to prohibit kickback conduct between the principal and individuals who do not directly interact with patients, serves as a wake-up call to the booming clinical laboratory testing industry, say attorneys at Kendall Brill.
-
Series
Law School's Missed Lessons: How To Make A Deal
Preparing lawyers for the nuances of a transactional practice is not a strong suit for most law schools, but, in practice, there are six principles that can help young M&A lawyers become seasoned, trusted deal advisers, says Chuck Morton at Venable.
-
From Clerkship To Law Firm: 5 Transition Tips For Associates
Excerpt from Practical Guidance
Transitioning from a judicial clerkship to an associate position at a law firm may seem daunting, but by using knowledge gained while clerking, being mindful of key differences and taking advantage of professional development opportunities, these attorneys can flourish in private practice, say attorneys at Lowenstein Sandler.
-
9th Circ.'s Trade Secrets Ruling Is A Win For DTSA Plaintiffs
The Ninth Circuit's recent decision in Quintara v. Ruifeng shifts the balance in federal trade secret litigation toward a more flexible, discovery-driven process, meaning that plaintiffs may be more likely to pursue claims under the Defend Trade Secrets Act, and early motions to strike or dismiss will face steep odds, say attorneys at Cooley.
-
Associates Can Earn Credibility By Investing In Relationships
As the class of 2025 prepares to join law firms this fall, new associates must adapt to office dynamics and establish credible reputations — which require quiet, consistent relationship-building skills as much as legal acumen, says Kyle Forges at Bast Amron.
-
Puzzling Out When Similar Insurance Claims Are Related
A recent decision in Virginia federal court shows that more than identical allegations of negligent business practices across two lawsuits may be necessary to satisfy the strict definition of relatedness under claims-made liability insurance policies, say attorneys at Hunton.
-
A Shifting Trend In FDA Form 483 Disclosure Obligations
A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird.
-
Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop
There are new rules for when and how evidence other than patents or printed publications can be considered in inter partes reviews, and while this change is intended to reflect current Federal Circuit precedent, the U.S. Patent and Trademark Office's memo seems to acknowledge tension with last month's Shockwave decision, say attorneys at Finnegan.
-
Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling
The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law.
-
Breaking Down The Proposed Hemp Bill
A proposed bill in the U.S. House of Representatives, recently approved by the House Appropriations Committee, contains a rider that would significantly change the definition of hemp and dramatically reshape the current hemp-derived product market, say attorneys at King & Spalding.
-
Assessing Federal Securities Class Action Stats In '25 So Far
The settlement amount as a percentage of damages in securities class actions has continued to decline in the first half of 2025, a trend that may be important for assessing exposure and risk in future securities litigation, say analysts at Analysis Group.
-
Series
Quilting Makes Me A Better Lawyer
Turning intricate patterns of fabric and thread into quilts has taught me that craftsmanship, creative problem-solving and dedication to incremental progress are essential to creating something lasting that will help another person — just like in law, says Veronica McMillan at Kramon & Graham.
-
How Agentic AI Is Testing The Limits Of Patent Law
While a recent Swiss court ruling suggests that human-centric rules regarding inventorship will likely remain in place for the near future, it captures a core tension confronting patent systems worldwide as the technology producing patent-worthy ideas is becoming increasingly autonomous, says Matthew Carey at Marshall Gerstein.
-
How To Prep For Potential Passage Of SAFER Banking Act
The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard.
-
A Former PTAB Judge Weighs The End Of Remote Hearings
Former Patent Trial and Appeal Board Judge Amanda Wieker, now at McGuireWoods, examines the costs and benefits of the PTAB's impending in-person hearing requirement, and offers suggestions for making the most out of this new regime.